https://www.selleckchem.com/products/gw9662.html
43) or 1-year (OR 0.47; 95%CI 0.15-1.44, p = 0.19), with a trend towards lower risk. Similar results were seen for mortality and wound complications, and when stratifying by indication. TXA was not associated with increased complications in current or former cancer patients undergoing arthroplasty. Future randomized studies of TXA in arthroplasty should include cancer patients; in the interim, clinicians should weigh the theoretical risks of TXA with the known benefits of reduced blood loss in oncology patients. TXA was not associated wi
Like
Comment
Share
